Joanne Taylor highlights the groundbreaking work of Gain Therapeutics in developing GT-02287, a GBA modulator, as a potential treatment for Parkinson’s disease. She discusses the origin of GT-02287, its mechanism of action, and preclinical findings demonstrating its efficacy in addressing key pathological features of Parkinson’s disease.

Gain Therapeutics is ready to share the latest R&D update on Parkinson’s Disease. This event is intended for all KOL’s, Analysts, Patient Advocates, and investors

Watch the video from 50 sec onwards to learn hear about Gain Therapeutics Gain Therapeutics was mentioned on Fox Business News as a company to

Beatriz Calvo-Flores Guzman, presented at the 20th Annual WORLDSymposium discussing preclinical data demonstrating that our clinical-stage GCase regulator provided neuroprotection & restored motor function in

This webinar, hosted by Force Family Office, features  Gain Therapeutics, a biotech company developing treatments for Parkinson’s disease and other neurodegenerative diseases. The speakers are

Gain Therapeutics will be attending JP Morgan HealthCare Conference Jan 8th to 11th, 2024 in San Francisco.   Representing will be: CEO Matthias Alder CFO Evan

 “The published data propose that strategies to alleviate dysfunction such as targeting GCase could be a new therapeutic opportunity for neurodegenerative diseases and lysosomal storage

Gain’s Clinical Candidate GT-02287 Earlier this month, Gain Therapeutics announced the dosing of the first two subjects in a Phase 1 clinical trial of GT-02287,

  In an engaging interview, journalist Jane King from LilaMax Media discusses cutting-edge allosteric therapies with Gain Therapeutics’ CEO, Matthias Alder, and their potential in

Biomarkers allow clinicians to measure the effects of treatment, helping determine how patients respond to therapeutic intervention. While biomarkers have been crucial in diseases such

Neurofilament light chain (NfL) is a protein found inside neurons in the brain. If axons die, for example, due to disease, NfL is released from

On the topic of standards and regulations, what has it been like to work with regulatory agencies such as the FDA and EMA (European Medicines

“Data! Data! Data! I can’t make bricks without clay.” This famous quote from Sherlock Holmes summarizes Dr. Terenzio Ignoni’s outlook on the future of drug

Give him the data, give him the facts, and Dr. Terenzio Ignoni will run with them. As the SVP of Technical Operations, Terenzio is in

We’re back with Ana Maria Garcia-Collazo, Ph.D. of Gain Therapeutics.  We ended Part 1 of our interview talking about the intersection of chemistry and computational

Wisdom is not hard to come by. Passion and enthusiasm are a different story. On a bright and sunny Thursday morning in April 2023, Ana

Part 2: When we left off speaking to Evan Ballantyne, Gain Therapeutics’ new CFO, he was sharing several stories about industry and career successes. Part

On March 29th 2023, Hartaj Singh (Oppenheimer Senior Research Biotechnology Analyst) moderated a virtual Fireside Chat panel with Xavier Barril, Ph.D. (Gain Therapeutics’ CTO), Brandon

On April 12, 2023, Gain Therapeutics announced Evan Ballantyne as the company’s new Chief Financial Officer. Ballantyne has been around the block. His humble demeanor

On Thursday, April 13, 2023, The Michael J. Fox Foundation (MJFF) announced a historic breakthrough1 in the development of Parkinson’s disease detection and diagnosis. The

Over 200 years ago, Dr. James Parkinson, a neurologist, geologist, and activist, published “An Essay on the Shaking Palsy” in 1817 which described the disease.

  Download : AD PD Infographic

On Wednesday, March 29th, Hartaj Singh (Oppenheimer Senior Research Biotechnology Analyst) moderated a virtual Fireside Chat panel with Gain Therapeutics’ CTO Xavier Barril, Ph.D. and

Virtual Fireside Chat: Computational Biology in Drug Discovery with Gain Therapeutics (GANX) CTO & Two Experts on Wednesday, March 29th at 12:00 p.m. EDT Listen

Download: SEE-Tx® Platform